Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC101 extension in CKD and metabolic acidosis
NCT03390842Phase 3Completed
- Sponsor
- Tricida, Inc.
- Start
- Dec 2017
- Primary completion
- Feb 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of veverimer in metabolic acidosis, chronic kidney disease (CKD), sponsored by Tricida, Inc.. Started Dec 2017; status: completed.
02
Drugs
veverimer
03
Conditions
metabolic acidosischronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03390842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390842.